Valeant planning hostile takeover bid as Botox maker Allergan rejects acquisition proposals
NEW YORK, N.Y. - Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals.
Valeant Pharmaceuticals International Inc. Chairman and CEO J. Michael Pearson said in a conference call Tuesday that proxies seeking support for its bid may be mailed in "the near-term."
He said that "It is clear Allergan's management and their board will never sit down and act in the interest of their shareholders." Pearson says the Canadian company believes an Allergan shareholder vote would "be overwhelmingly in support of the deal."
The latest bid from Valeant and Bill Ackman's Pershing Square Capital Management is worth $53 billion.
California-based Allergan Inc. has repeatedly rejected offers as underpriced and risky.
Read more Business News
- Dream wedding for dying manVernon / N. Okanagan - 7:23 am
- Puppy attacked at parkKelowna - 11:34 am
- Terrorist acts in the 1950sPenticton / S. Okanagan - 5:00 am
- Alaska wants say in BCBC - 1:14 pm
|QHR Technologies Inc||1.20||-0.01|
|Anavex Life Sciences||0.265||+0.005|
|Copper Mountain Mining||2.99||+0.11|
|Sunrise Resources Ltd||0.025||-0.005|
|Mission Ready Services||0.26||+0.045|
Photo: ContributedI would call it a joy ride... You see a planned project or business has a destination. It may be an ongoing revenue stream, it may be a business value or an exit strategy. If you don...
Establishing a joint account may seem like a great strategy at first glance. However, there are many factors that must be considered before taking this action. This article will explore the use of &ls...
Let’s face it; nobody wants to pay for legal services if they do not have to, but if you have been injured in an accident you may have thought about hiring a lawyer to help you navigate your cla...